Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer
10.3969/j.issn.1674-7445.2021.03.004
- VernacularTitle:肝癌肝移植术后复发转移的免疫治疗
- Author:
Shaoru LIU
1
;
Leibo XU
Author Information
1. Department of Biliary and Pancreatic Surgery, Organ Transplantation Center, the Memorial Hospital of Sun Yat-sen University, Guangzhou 510288, China
- Publication Type:Research Article
- Keywords:
Primary liver cancer;
Liver transplantation;
Recurrence and metastasis;
Programmed cell death protein 1 (PD-1);
Immunotherapy;
Immune checkpoint inhibitor (ICI);
Acute rejection;
Immune escape;
Nivolumab;
Pembrolizumab
- From:
Organ Transplantation
2021;12(3):272-
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer (liver cancer) is one of the main indications of liver transplantation in China. Nevertheless, the 5-year survival rate of liver transplant recipients is lower than 50%. Recurrence and metastasis after operation are the main causes affecting the long-term survival of the recipients. At present, immunotherapy, represented by programmed cell death protein 1(PD-1)/programmed cell death protein-ligand 1(PD-L1) immune checkpoint inhibitor, has achieved remarkable clinical efficacy in the treatment of middle-stage and advanced liver cancer. However, whether it can be applied in recipients with recurrence and metastasis after liver transplantation for liver cancer remains controversial. The main reason is that it may cause acute rejection at the same time. In this article, the research progresses on the application of immunotherapy in recipients with recurrence and metastasis after liver transplantation for liver cancer were reviewed, aiming to improve the survival rate of recipients undergoing liver transplantation forliver cancer.
